BriLife (IIBR-100) Vaccine Description
Brilife (IIBR-100) is a recombinant vesicular stomatitis virus (VSV), an animal virus that does not cause disease in humans, and where the spike protein was replaced with that of SARS-CoV-2 that “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2.
Brilife is a vector-based vaccine that takes VSV and genetically engineers it to express the spike protein of the SARS-CoV-2 betacoronavirus on its envelope. The human body recognizes the spike protein expressed on the envelope and begins to develop an immunological response.
On June 19, 2020, a non-peer-reviewed study concluded 'the generated rVSV-ΔG-spike, a recombinant replication-competent VSV-based vaccine candidate expressing the SARS-CoV-2 spike protein. The rVSV-ΔG-spike resembles the SARS-CoV-2 in spike expression properties, antigenicity, and ability to induce neutralizing antibody production. Moreover, single-dose vaccination of hamsters with rVSV-ΔG-spike elicits a safe, effective, and sufficient neutralizing antibody response against the SARS-CoV-2 challenge.
The vaccination protected SARS-CoV-2 inoculation, as manifested in the rapid return to normal physiological parameters lung protection and rapid viral clearance. These results pave the way for further examination of rVSV-ΔGspike in clinical trials as a vaccine against SARS-CoV-2.'
“Our final goal is 15 million doses for the residents of the State of Israel and our close neighbors,” said Prof. Shmuel Shapira, director of the Israel Institute for Biological research, reported local media on October 26, 2020.
Sheba Medical Center and Hadassah Medical Center stated they were chosen for a COVID-19 vaccine's initial trials. Both of these Israeli hospitals were selected because they have large facilities for clinical research.
The phase 2 study of IIBR-100 was last updated on January 5, 2021.
On November 27, 2020, Jerusalem Post reported, “We are pleased to announce that the first phase of the clinical research trial of the coronavirus vaccine was a success,” said the director of the clinical research unit at Hadassah, Prof. Yossi Karko.
The Israel Institute for Biological research (IIBR) was established in 1952 as a governmental research institute founded by scientists from the IDF Science Corps and academic organizations. IIBR is located in the city of Ness Ziona, Israel.
STOP COVID Clinical Trial Sponsorship
COVID-19 study now enrolling newly diagnosed patients. Click here for more information.
BriLife (IIBR-100) Vaccine Indication
Brilife is indicated to prevent COVID-19 disease from infection with the virus SARS-CoV-2.
No pediatric, oncology or pregnancy vaccine efficacy has been disclosed.
BriLife (IIBR-100) Vaccine News
January 5, 2021 - Local media reported the first person to receive a dose of BriLife vaccine's expanded Phase II trial was inoculated at Barzilai Medical Center in Ashkelon. Volunteers had already been inoculated at Sheba Medical Center, Tel Hashomer, and Hadassah-University Medical Center, where the Phase I trial took place.
December 29, 2020 - As the Phase II trial for Israel’s Brilife vaccine got underway at Sheba Medical Center, Dr. Eytan Ben Ami, who is overseeing the testing, admitted that Israel’s move toward COVID-19 safety is creating new challenges. Israel is racing to become the first country in the world with herd immunity. Some 10 million doses of Pfizer and Moderna vaccines are reportedly scheduled to arrive in the coming months.
December 14, 2020 - The Israeli Health Ministry has approved the launch of Phase II clinical trial for the Israel Institute of Biological Research’s coronavirus vaccine candidate, known as Brilife. The trial begins at Sheba Medical Center, Tel Hashomer, and then expanded to other medical centers across the country.
November 30, 2020 - Speaking at the Knesset on Monday, Israel Institute for Biological Research head Dr. Shmuel Shapira said that “we should have been in Phase III, and now we will only reach it by April."
November 27, 2020 - Hadassah-University Medical Center and Sheba Medical Center reported that they had administered the Brilife coronavirus vaccine candidate to 80 volunteers, thus completing the Phase I clinical trial.
November 14, 2020 - Hadassah-University Medical Center has vaccinated 23 people against the novel coronavirus using the Israel Institute for Biological Research’s coronavirus vaccine candidate Brilife, the hospital said Friday. “All 23 participants in their 20s to 50s have had the vaccine in the last two weeks and are feeling well,” said Prof. Yossi Karko, director of the Center for Clinical Research at Hadassah. “They have not suffered from any unusual side effects or medical problems following the vaccine, other than temporary sensitivity at the site of injection – as expected.”
November 8, 2020 - Four women who were selected to participate in the human trial of "Brilife," the Israeli Institute for Biological Research's coronavirus vaccine, were vaccinated at Hadassah University Medical Center in Jerusalem's Ein Kerem. All four women were in their 20s - 30s and had been medically tested and found suitable to participate in the trial.
November 1, 2020 - The human trial of Brilife, its coronavirus vaccine candidate, launched by injecting two people – one at Hadassah-University Medical Center in Jerusalem's Ein Kerem and one at Sheba Medical Center at Tel Hashomer.
October 26, 2020 - Testing the BriLife vaccine developed at Israel Institute for Biological Research begins at Hadassah and Sheba medical centers on healthy volunteers.
October 20, 2020 - Israel names its coronavirus vaccine candidate: Brilife.
June 21, 2020 - ISRAEL21c reported that a single dose of the IIBR’s recombinant VSV-∆G-spike vaccine “results in rapid and potent induction of neutralizing antibodies against SARS-CoV-2” in Syrian golden hamsters in a successful preclinical trial. It was also tested successfully in mice, rabbits, and pigs, paving the way to human trials.
BriLife (IIBR-100) Vaccine Clinical Trials
Clinical Trial NCT04608305: Evaluate the Safety, Immunogenicity, and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine - Last Update Posted: January 5, 2021.
- In this Phase 1 study, a vaccine developed by IIBR for SARS-CoV-2 virus will be assessed for its safety and potential efficacy in volunteers.
- The study is comprised of two phases, a dose-escalation phase (phase I) during which subjects (18-55 years old) will be randomly allocated to receive a single administration of IIBR-100 100 at the low, mid, or high dose of saline or two administrations of IIBR-100 at a low dose, or saline, 28 days apart.
- The expansion Phase 2 study will begin with larger cohorts, as well as elderly age subjects, will be randomly allocated to receive a single administration of IIBR-100 at low, mid, or high dose or saline, or two administrations of IIBR-100 at a low dose (prime-boost) or saline, 28 days apart. The subjects will be followed for up to 12 months post last vaccine administration to assess the vaccine's safety and efficacy.
- Phase 3 large scale trial is expected to begin in the spring of 2021 and will test the effectiveness of Brilife with up to 30,000 volunteers.
- Estimated Primary Completion Date: May 1, 2021.